Viracta Therapeutics (VIRX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Overview

Viracta Therapeutics was a precision oncology company developing targeted therapies for Epstein-Barr virus (EBV)-associated cancers, a significant unmet medical need. Its core strategy centered on a proprietary 'lytic induction therapy' platform, which combined a viral activator (nanatinostat) with an antiviral prodrug (valganciclovir) to selectively kill virus-infected cancer cells. The company's lead program, Nana-val, advanced into Phase 2 trials for relapsed/refractory EBV+ lymphomas and a Phase 1b/2 trial for nasopharyngeal carcinoma. Following strategic reviews and financial challenges, Viracta wound down its operations in 2024.

OncologyInfectious Disease (Virus-associated)

Technology Platform

A proprietary 'lytic induction therapy' platform that combines a viral activator drug (nanatinostat) to induce viral replication in latent virus-infected cancer cells with an antiviral prodrug (valganciclovir) that is selectively activated by the viral kinase to cause targeted tumor cell death.

Pipeline

3

3 drugs in pipeline

Drug	Indication	Stage
Nanatinostat in combination with valganciclovir	Epstein-Barr Virus Associated Lymphoma	Phase 2
Nanatinostat + Valganciclovir + Pembrolizumab	Nasopharyngeal Carcinoma	Phase 1
[14C]-Nanatinostat + Nanatinostat (free base) tablets in com...	Advanced Cancer	Phase 1

Opportunities

The core opportunity was a large, unaddressed market in EBV-associated cancers, with the potential for a first-in-class, targeted oral therapy.

Success could have established a new treatment paradigm and opened avenues for expansion into other virus-linked malignancies.

Risk Factors

The primary realized risk was an inability to secure financing in a difficult capital market, leading to operational wind-down.

Additional risks included clinical trial failure, regulatory hurdles, and future competition in the emerging field of viral oncology.

Competitive Landscape

Competition was limited but emerging. Direct rivals included complex, personalized EBV-specific T-cell therapies and broadly used checkpoint inhibitors. Viracta's Nana-val aimed to differentiate with an off-the-shelf, oral, and mechanistically targeted approach, holding a first-mover advantage in late-stage clinical development for this niche.

More companies in Oncology (General) →More companies in United States →